九州大学 研究者情報
発表一覧
前田 高宏(まえだ たかひろ) データ更新日:2022.06.30

教授 /  医学研究院 附属プレシジョンメディシン研究センター プレシジョン医療学


学会発表等
1. Sasaki K, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, Nakao F, Akahane K, Inukai T, Verhoeyen E, Akashi K and Maeda T, Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL, American Society of Hematology annual meeting, Atlanta, USA, 2021.12, Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL, also known as BCR-ABL1-like ALL) is a disease entity of B-cell ALL that exhibits a gene expression profile, similar to that of Philadelphia chromosome-positive ALL. Ph-like ALL is categorized into two disease subtypes: “ABL-class”- and “CRLF2/JAK pathway”-types, both of which harbor gene alterations that constitutively activate cytokine/growth factor-related signals. Ph-like ALL with the CRLF2 rearrangement exhibits poor clinical outcomes and is the most common subtype of Ph-like ALL. Tyrosine kinase inhibitor (TKI)-based treatment regimens are effective in treating ABL-class type Ph-like ALL; however, no standard regimen has been established for the CRLF2/JAK pathway type. While multiple chemotherapeutic regimens, including Ruxolitinib monotherapy and/or its combination with chemotherapy, are being tested, their efficacy is reportedly limited. Thus, novel approaches are needed to treat CRLF2/JAK pathway type Ph-like ALL, in particular for CRLF2-rearranged (CRLF2-r) ALL..
2. Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T., PAICS, a de novo purine synthetic enzyme, is a novel target for AML therapy., American Society of Hematology annual meeting, Orland, USA, 2019.09.
3. SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T., CRISPR-Cas9 screen identifies XPO7 as a potential therapeutic target for TP53-mutated AML., American Society of Hematology annual meeting, Orland, USA, 2019.09.
4. Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T. , CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance in AML. American Society of Hematology annual meeting, , American Society of Hematology annual meeting, Orland, USA, 2019.09.
5. Sasaki K, Miyawaki K, Semba Y, Kato K, Nogami J, Sugio T, Miyamoto T, Ito Y, Nagafuji K, Maeda T, Akashi K. , A fast and accurate diagnostic method for Ph-like ALL using the nCounter system., American Society of Hematology annual meeting, Orland, USA, 2019.09.
6. Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive DLBCL., American Society of Hematology annual meeting, Orland, USA, 2019.09.
7. Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T. , Genome-wide CRISPR screen identifies PAICS, and enzyme involved in de novo purine synthesis, as a potential target for AML therapy., SOHO 2019, 2019.09.
8. Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive aggressive DLBCL., SOHO 2019, 2019.09.
9. SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T., CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML., SOHO 2019, 2019.09.
10. Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive aggressive DLBCL. , FASEB: The Hematologic Malignancies Conference., 2019.07.
11. Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T. , Genome-wide CRISPR screen identifies PAICS, and enzyme involved in de novo purine synthesis, as a potential target for AML therapy., FASEB: The Hematologic Malignancies Conference., 2019.07.
12. SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T. , CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML., FASEB: The Hematologic Malignancies Conference., 2019.07.
13. Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T. , CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance. FASEB: The Hematologic Malignancies Conference., FASEB: The Hematologic Malignancies Conference., 2019.07.
14. Sasaki K, Miyawaki K, Semba Y, Kato K, Nogami J, Sugio T, Miyamoto T, Ito Y, Nagafuji K, Maeda T, Akashi K., A fast and accurate diagnostic method for Ph-like ALL using the nCounter system., FASEB: The Hematologic Malignancies Conference., 2019.07.
15. 前田高宏, プレシジョン血液腫瘍学:次世代シークエンスの導入が臨床現場にもたらすこと, 第80回 日本血液学会総会, 2018.10.
16. 前田高宏, Identifying novel targets for leukemia therapy using the CRISPR/Cas9 gene-editing tool, 第77回日本癌学会学術総会, 2018.09.
17. 前田高宏, 全ゲノムCRISPR-Cas9スクリーニングによる白血病細胞の増殖に必要なpre-mRNA合成制御因子の同定, 第77回日本癌学会学術総会, 2018.09.
18. Takahiro Maeda, Leukemia-specific dependence on a nuclear pre-mRNA processing pathway regulated by the DCPS decapping enzyme, Novel insights into nuclear events in cancer, 2018.06.
19. Takahiro Maeda, Genome-Wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway, American Society of Hematology Annual Meeting, 2017.12.
20. Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg V.A.C., Cole MA, Trevino CM, Ishikawa Y, Yao Qiuming, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T. , Genome-wide CRISPR/Cas9 screen reveals that the DCPS scavenger decapping enzyme is essential for AML cell survival, American Society of Hematology Annual Meeting, 2017.12.
21. Takahiro Maeda, Regulation of fetal hemoglobin expression by the LRF transcription factor, Japanese Society of Hematology, 2017.10.
22. Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg V.A.C., Cole MA, Trevino CM, Ishikawa Y, Yao Qiuming, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T. , Targeting nuclear RNA metabolic pathways for the treatment of acute myeloid leukemia, Japanese Society of Hematology, 2017.10.
23. Takahiro Maeda, Transcription factor LRF is a repressor of γ-globin expression., Gamma Globin Induction Translational Mini-Workshop. Children’s Hospital Boston, 2016.05.
24. Takahiro Maeda, Identification of novel targets for AML therapy via a genome-wide CRISPR-Cas9 screen., 5th Cancer Stem Cell Symposium, 2016.11.
25. Takahiro Maeda, Regulation of lympho-hematopoiesis by the transcription factor LRF/ZBTB7A, Japanese Society of Immunology, 2016.11.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」